Skip to content

Episealer® Knee

The only individualised implant for focal cartilage lesions in the knee

Learn more

Episealer® Talus

Personalised implant for osteochondral lesions in the ankle

Learn more

Episealer® Patellofemoral System

For patients with osteoarthritis of the patellofemoral joint

Learn more

The Episurf Process

To ensure you receive the best possible treatment for your cartilage lesion, every step in the process focuses on you.

MRI Scan
To obtain a clear image of the lesion and your knee, 2D and 3D MRI scans are taken
Damage Marking Report
These images are then used to create a virtual 3D model and visualisation of your knee joint
Episealer
This 3D model is the basis for the design of your individualised Episealer implant

Episealer Products

Patient testimonials

Press releases and financial reports

Conversion of convertibles in a nominal amount of SEK 9,279,911 to 206,220,244 Class B shares

On 1 October 2026, Episurf Medical AB (publ) (“Episurf“) issued, in relation to the closing of the acquisition of the Hudiksvall portfolio, convertibles in an aggregated nominal amount of SEK 64,780,000. Convertibles in a nominal amount of SEK 9,279,911 have, as of the date of this press release, at the request from holders of convertible debentures, been converted into 206,220,244 Class B shares in Episurf at a conversion price of SEK 0.045 per share in…

    The Board of Directors of Episurf has resolved on an issue of Class B shares and convertibles as consideration for the acquisition of properties and completed a conversion of convertibles

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR DISCLOSURE WOULD BE IN VIOLATION OF APPLICABLE LAWS OR REQUIRE ADDITIONAL REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO THE SECTION “IMPORTANT INFORMATION” AT THE END OF…

      Episurf Medical completes acquisition of property portfolio in Hudiksvall

      Episurf Medical AB (publ) (Nasdaq Stockholm: EPIS B) (“Episurf” or the “Company”) has today, through a wholly owned subsidiary, completed the acquisition of eight properties in Hudiksvall with an agreed underlying property value of SEK 300 million. With the exception of the property Åvik 26:14, the properties constitute the Non-completed Property Portfolio described in the Company’s press release of 30 December 2025. The properties have a total leasable area of approximately 16,300 m², annual rental…